Inflammation and the Host Response to Injury (Burns)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by National Institute of General Medical Sciences (NIGMS).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Institute of General Medical Sciences (NIGMS)
ClinicalTrials.gov Identifier:
NCT00257244
First received: November 18, 2005
Last updated: August 12, 2009
Last verified: August 2009

November 18, 2005
August 12, 2009
April 2004
 
 
 
Complete list of historical versions of study NCT00257244 on ClinicalTrials.gov Archive Site
 
 
 
 
 
Inflammation and the Host Response to Injury (Burns)
Inflammation and the Host Response to Injury

The purpose of this study is to help improve our understanding of the biology involved in the body's response to serious trauma or burn injury. The host response to trauma and burns is a collection of physiological and pathophysiological processes that depend critically upon the regulation of the human innate immune system, with particular emphasis on the inflammatory component of that system. No single research center or small group of centers has the capacity to delineate the integrated response of this complex biological system, which involves multiple molecular and genetic interactions that vary in time. Our proposal promotes the identification of important dynamic relationships that regulate the integration of this complex biological system, with the expectation that this understanding will ultimately impact the diagnosis, prognosis, and treatment of the hospitalized, severely injured patient.

This large-scale collaborative project provides the means to acquire the necessary new knowledge directly in humans. Knowledge will be acquired using diverse state-of-the-art genomic and proteomic technologies, a highly complex clinical, proteomic, and genomic database, as well as newly-developed, novel analytical tools to probe this complex dataset. Our analytical capabilities at the genomic and proteomic level are now rapidly evolving and our ability to link these genomic and proteomic data to pathways and functional modules will help us more closely link this cellular data to immunological processes and ultimately, to the phenotypic response (i.e., trajectory) in the injured host. As a result, potential interventions, whether through our Program or other funding mechanisms, can be more effectively designed.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Retention:   Samples Without DNA
Description:

Plasma, blood leukocyte nucleic acids (RNA), solid tissue nucleic acids (only RNA, no DNA)

Non-Probability Sample

Acute hospitalized burn patients

  • Trauma
  • Burns
  • Multiple Organ Failure
 
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
280
September 2009
 

Inclusion Criteria:

  • Burn patients of all ages with 20% or greater of total body surface area burns that require surgical treatment
  • Burn patients admitted to the burn unit within 96 hours (4 days) of burn injury

All patients meeting these criteria are entered into the epidemiologic database and assessed for specific exclusion criteria to establish whether serial blood draws are warranted.

Exclusion Criteria:

  • Injury caused by chemical agent
  • Deep injury caused by conduction of electrical current or charge
  • Decision not to treat due to severity of injury
  • Anoxic brain injury that is not expected to result in complete recovery
  • Associated multiple injuries exclusive of burns (ISS >=25)
  • Pre-morbid condition: Severe congestive heart failure (measured ejection fraction <20%)
  • Pre-morbid condition: Malignancy currently under treatment
  • Pre-morbid condition: Medical condition requiring systemic glucocorticoid treatment
  • Pre-morbid condition: current systemic immunosuppression for organ transplant or chronic inflammatory condition
Both
 
No
Contact: David N Herndon, MD 409-770-6733 dherndon@utmb.edu
Contact: Ronald G Tompkins, MD, ScD 617-726-3447 rtompkins@partners.org
United States
 
NCT00257244
2 U54 GM062119_burn, 2 U54 GM062119
Yes
Ronald G. Tompkins, Principal Investigator, Massachusetts General Hospital
National Institute of General Medical Sciences (NIGMS)
 
Principal Investigator: Ronald G. Tompkins, MD, ScD Massachusetts General Hospital
National Institute of General Medical Sciences (NIGMS)
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP